Journal
LEUKEMIA
Volume 23, Issue 4, Pages 729-738Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.349
Keywords
AML; FLT3 mutation; Gadd45 alpha; FLT3-ITD mutation
Categories
Funding
- US National Institutes of Health [R01 HL60657]
- National Health and Medical Research Council of Australia [453408]
- Peter Nelson Leukemia Research Fellowship
- Leukemia Foundation of Australia
- Cancer Council of SA
Ask authors/readers for more resources
The tumor suppressor Gadd45 alpha was earlier shown to be a repressed target of sustained receptor-mediated ERK1/2 signaling. We have identified Gadd45 alpha as a downregulated gene in response to constitutive signaling from two FLT3 mutants (FLT3-ITD and FLT3-TKD) commonly found in AML, and a leukemogenic GM-CSF receptor trans-membrane mutant (GMR-V449E). GADD45A mRNA downregulation is also associated with FLT3-ITD+ AML. Sustained ERK1/2 signaling contributes significantly to receptor-mediated downregulation of Gadd45 alpha mRNA in FDB1 cells expressing activated receptor mutants, and in the FLT3-ITD+ cell line MV4;11. Knockdown of Gadd45 alpha with shRNA led to increased growth and survival of FDB1 cells and enforced expression of Gadd45 alpha in FDB1 cells expressing FLT3-ITD or GMR-V449E resulted in reduced growth and viability. Gadd45 alpha overexpression in FLT3-ITD+ AML cell lines also resulted in reduced growth associated with increased apoptosis and G(1)/S cell cycle arrest. Overexpression of Gadd45 alpha in FDB1 cells expressing GMR-V449E was sufficient to induce changes associated with myeloid differentiation suggesting Gadd45 alpha downregulation contributes to the maintenance of receptor-induced myeloid differentiation block. Thus, we show that ERK1/2-mediated downregulation of Gadd45 alpha by sustained receptor signaling contributes to growth, survival and arrested differentiation in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available